Gastrointestinal symptomsparticularly nausea, vomiting, diarrhoea, and constipationare the most frequently reported adverse effects of GLP-1 receptor agonists, occurring in 2050% of patients depending on the specific agent and dose according to clinical trials and SmPC data
Third, TZD increases insulin sensitivity in muscle and liver [24]
Indeed, hippocampal neurons displayed significant DNA fragmentation (TUNEL + ), and activated caspase-3 when determined by immunohistochemistry (Perkins et al., 2003)
The typical GLP-1 microdosing schedule takes 20-32 weeks to get the same therapeutic level (some patients may stay on a microdose if they feel happy with their weight loss)
This approach entails a shift from a traditional chronic therapy model to a more dynamic, symptom-guided treatment strategy
FDA-approved medications for these conditions have been scarce